Financial Performance - The company's revenue for Q3 2024 reached ¥5.35 billion, representing a year-on-year increase of 1.49%[2] - Net profit attributable to shareholders for Q3 2024 was ¥251.71 million, an increase of 8.68% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥246.28 million, up 6.96% year-on-year[2] - For the first nine months of 2024, the company achieved a total revenue of ¥15.99 billion, a growth of 2.41% year-on-year[4] - The company reported a basic earnings per share of ¥0.63 for Q3 2024, a decrease of 1.56% compared to the previous year[3] - The total operating revenue for the first three quarters of 2024 reached CNY 15,992,976,622.19, an increase from CNY 15,616,596,259.20 in the same period of 2023, representing a growth of approximately 2.4%[18] - The net profit for the first three quarters of 2024 was CNY 745,538,643.11, up from CNY 719,540,098.92 in 2023, reflecting a growth of approximately 3.6%[20] - The earnings per share (EPS) for the first three quarters of 2024 was CNY 1.87, slightly higher than CNY 1.86 in the same period of 2023[20] Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥22.03 billion, reflecting a year-on-year increase of 9.29%[3] - The company's equity attributable to shareholders was ¥7.79 billion, which is a 17.75% increase from the previous year[3] - The company's total current assets as of September 30, 2024, amount to ¥19,488,514,176.24, an increase from ¥17,316,669,959.11 at the end of 2023[13] - The total liabilities increased to CNY 13,766,814,261.86 in Q3 2024 from CNY 13,095,714,302.96 in Q3 2023, marking an increase of about 5.1%[17] - The total non-current liabilities reached CNY 1,584,789,881.33 in Q3 2024, up from CNY 1,481,953,010.17 in Q3 2023, indicating an increase of approximately 6.9%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 25,745[9] - The largest shareholder, Zhu Chaoyang, holds 101,032,795 shares, accounting for 25.32% of total shares, with 32,720,000 shares pledged[9] Cash Flow and Investments - The company's cash and cash equivalents decreased to ¥2,910,521,614.57 from ¥3,147,667,970.80[12] - The net cash flow from operating activities increased significantly to CNY 122,979,630.21, compared to CNY 19,513,898.36 in the previous year, marking a substantial improvement[21] - The company reported a net cash outflow from investment activities of CNY -105,558,116.78, slightly better than the previous year's outflow of CNY -107,664,989.20[22] - Total cash inflow from financing activities reached CNY 5,261,485,698.29, up from CNY 3,838,787,714.80 in the same period last year, indicating strong financing support[22] - The net cash outflow from financing activities was CNY -784,153,602.86, compared to CNY -556,927,054.79 in the previous year, reflecting increased financial obligations[22] Operational Segments - The wholesale segment generated ¥1.27 billion in revenue, accounting for 79.80% of total revenue, with a slight decrease of 0.14% year-on-year[5] - The retail segment saw a revenue increase of 16.49%, reaching ¥239.54 million, contributing 15.05% to total revenue[5] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to CNY 21,663,634.24, compared to CNY 18,891,611.65 in 2023, indicating an increase of about 9.4%[18] Tax and Charges - The company reported a decrease in tax and additional charges to CNY 41,658,315.77 in Q3 2024 from CNY 47,254,968.10 in Q3 2023, a reduction of approximately 11.3%[18] Inventory and Receivables - The company's inventory has increased to ¥2,996,127,418.39 from ¥2,306,175,089.80 year-over-year[13] - The accounts receivable increased to ¥11,733,535,450.89 from ¥10,443,408,461.97 year-over-year[12]
柳药集团(603368) - 2024 Q3 - 季度财报